Related Experiment Videos
Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines
W W Li1, C Cordon-Cardo, Q Chen
1Laboratory of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
Four new cell lines were established from patients with soft tissue sarcomas. Drug sensitivity as well as genotypic characterization, which may be related to drug sensitivity in these cell lines, was determined. Karyotype, H-ras, c-myc and mutant p53 gene expression, Rb, G1- and S-phase cyclins, E2F and major cyclin/CDK inhibitors such as p16 and p21 and p-glycoprotein were analyzed using cytogenetic, Northern blot and immunological methods. Drug sensitivity was determined using growth inhibition tests. These cell lines differed in their morphology and growth rates, forming colonies in soft agar with a cloning efficiency of 4.3-13.4%, and 3 of the 4 cell lines grew in nude mice. Cytogenetic analysis of cell lines revealed highly aneuploid karyotypes. Deletion and/or translocation of chromosome 17 was seen in HS-16, HS-18 and HS-30 cells, and both copies of chromosome 13 were lost or re-arranged in the HS-18 cell line. Mutant p53 protein was present in all 4 cell lines. HS-18 cells showed no expression of the Rb protein and high levels of expression of E2F, cyclin A, cyclin E and CDK2. HS-16 expressed a higher level of cyclin D than the other 3 cell lines. p21WAF1 expression was seen in all cell lines, but p16ink4 was expressed only in HS-30 and HS-42 cell lines. These cell lines were sensitive to taxol and relatively resistant to methotrexate, vinblastine and 5-fluorouracil when compared with the fibrosarcoma cell line HT-1080. These new cell lines should provide a useful model for the study of soft tissue sarcomas and for evaluating new drugs or treatments.
Insights
Four new soft tissue sarcoma cell lines were developed for research. These models show varied genetic profiles and drug sensitivities, offering a valuable tool for studying sarcomas and testing new therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Soft tissue sarcomas are a heterogeneous group of cancers.
- Developing reliable cell line models is crucial for understanding sarcoma biology and drug resistance.
Purpose of the Study:
- To establish and characterize new cell lines derived from soft tissue sarcomas.
- To analyze the genotypic features and drug sensitivities of these novel cell lines.
Main Methods:
- Cell line establishment from patient samples.
- Comprehensive genotypic analysis including karyotyping, gene expression (H-ras, c-myc, p53, Rb, cyclins, E2F, p16, p21, p-glycoprotein) via cytogenetics, Northern blot, and immunological methods.
- Drug sensitivity testing using growth inhibition assays.
Main Results:
- Four distinct soft tissue sarcoma cell lines were successfully established, exhibiting variable morphology, growth rates, and tumorigenicity in vivo.
- All cell lines harbored mutant p53, and chromosomal abnormalities involving chromosomes 17 and 13 were observed in specific lines.
- Differential expression of cell cycle regulators (Rb, cyclins, E2F, p16, p21) and p-glycoprotein was noted.
- The cell lines demonstrated sensitivity to taxol and relative resistance to methotrexate, vinblastine, and 5-fluorouracil compared to a standard fibrosarcoma line.
Conclusions:
- The newly established cell lines represent valuable preclinical models for soft tissue sarcoma research.
- Genotypic characterization provides insights into potential mechanisms of drug sensitivity and resistance.
- These models can facilitate the evaluation of novel therapeutic strategies for soft tissue sarcomas.